Table 4.
Adjusted odds ratios of positive NPS test according to age and HT usage in Sample B (females, N = 4521).
| Model B | Total N = 4,521 | Negative N = 3,496%=77.3 | Positive N = 1,025%=22.7 | Adjusted OR (95%CI) | |||
|---|---|---|---|---|---|---|---|
| AGE | |||||||
| Females aged≥60 | 267 | 15,4 | 428 | 12.2 | 267 | 26.1 | 1 (ref) |
| Females aged 50–60 | 283 | 27,9 | 977 | 28.0 | 283 | 27.6 | 0.69 (0.53–0.90) |
| Females aged <50 | 475 | 56,8 | 2091 | 59.8 | 475 | 46.3 | 0.62 (0.48–0.80) |
| HORMONAL THERAPY° | N | % | N | % | |||
| Never-HT users | 595 | 52,4 | 1773 | 50.7 | 595 | 58.1 | 1 (ref) |
| HT users | 430 | 47,6 | 1723 | 49.3 | 430 | 42.0 | 0.95 (0.81–1.10) |
| AGE X HORMONAL THERAPY | |||||||
| Females never-HT users aged≥60 | 219 | 10,8 | 270 | 7.7 | 219 | 21.4 | 1 (ref) |
| Females HT users aged ≥60 | 48 | 4,6 | 158 | 4.5 | 48 | 4.7 | 0.54 (0.36–0.80) |
| Females never-HT users aged 50–60 | 159 | 15,2 | 530 | 15.2 | 159 | 15.5 | 0.57 (0.42–0.77) |
| Females HT users aged 50–60 | 124 | 12,6 | 447 | 12.8 | 124 | 12.1 | 0.57 (0.41–0.79) |
| Females never-HT users aged <50 | 217 | 26,3 | 973 | 27.8 | 217 | 21.2 | 0.50 (0.37–0.67) |
| Females HT users aged <50 | 258 | 30,4 | 1118 | 32.0 | 258 | 25.2 | 0.52 (0.38–0.69) |
Never-HT users as reference category.
Model adjusted for age°, education, employment status, area of residence, healthcare professionals, physical activity, smoking status, living with at risk co-habitants, contact with COVID-19 cases, heart diseases, depression, liver and metabolic diseases, flu and anti-pneumococcal vaccine, anti-inflammatory and oncological drugs.